Acquired Resistance To Egfr Inhibitors In Glioblastoma Is Associated With Urokinase-Type Plasminogen Activator-Mediated Suppression Of Bim

Jill Wykosky,Jingjing Hu,Tiffany Taylor, Genaro R. Villa,German Gomez,Paul S. Mischel,Steven L. Gonias,Webster Cavenee,Frank Furnari

Neuro-oncology（2013）

引用 0|浏览3

暂无评分

摘要

The EGF receptor (EGFR) is the most commonly amplified or mutated gene in glioblastoma (GBM), but therapeutic targeting with small molecule tyrosine kinase inhibitors (TKIs) is limited by inherent and acquired resistance. Moreover, GBM is a highly heterogeneous disease and as a result, mechanisms of

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要